Dashboard
Manage Tickers

VRNAVerona Pharma plc

Nasdaq veronapharma.com


$ 14.83 $ 0.10 (0.68 %)    

Friday, 10-May-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 14.85
$ 14.73
$ 0.00 x 0
$ 0.00 x 0
$ 14.73 - $ 15.08
$ 11.83 - $ 23.54
762,317
na
9.59B
$ 1.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-07-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 03-03-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

verona-pharma-q1-2024-gaap-eps-004-beats-022-estimate
Verona Pharma Q1 2024 GAAP EPS $(0.04) Bea...
05/09/2024 11:19:09

verona-pharma-announces-650m-strategic-financing-with-oaktree-and-omers-cash-runway-extended-beyond-2026
Verona Pharma Announces $650M Strategic Fi...
05/09/2024 11:18:02

verona-pharma-to-present-additional-analyses-of-phase-3-enhance-studies-in-copd-at-ats-2024
Verona Pharma To Present Additional Analys...
05/02/2024 07:44:15

PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an ...

piper-sandler-maintains-overweight-on-verona-pharma-raises-price-target-to-36
Piper Sandler Maintains Overweight on Vero...
04/16/2024 11:48:53

Piper Sandler analyst Yasmeen Rahimi maintains Verona Pharma (NASDAQ:VRNA) with a Overweight and raises the price target fro...

hc-wainwright--co-reiterates-buy-on-verona-pharma-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Vero...
03/04/2024 12:09:38

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

wedbush-reiterates-outperform-on-verona-pharma-maintains-33-price-target
Wedbush Reiterates Outperform on Verona Ph...
03/01/2024 13:37:02

Wedbush analyst Liana Moussatos reiterates Verona Pharma (NASDAQ:VRNA) with a Outperform and maintains $33 price target.

earnings-scheduled-for-february-29-2024
Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

verona-pharma-q4-eps-002-flat-yoy-cash-balance-of-2718m
Verona Pharma Q4 EPS $(0.02), Flat YoY, Ca...
02/29/2024 07:04:24

earnings-preview-for-verona-pharma
Earnings Preview For Verona Pharma
02/28/2024 17:01:45

hc-wainwright--co-reiterates-buy-on-verona-pharma-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Vero...
01/22/2024 11:14:29

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

Core News & Articles
Verona Pharma Secures Up To $400M In Finan...
01/02/2024 07:13:24

Under the terms of the debt facility, the Company drew $50 million at closing, and may draw, subject to certain conditions prec...

verona-pharmas-promising-copd-treatment-puts-it-in-gsks-acquisition-crosshairs-analysts-predict-big-moves
Verona Pharma's Promising COPD Treatment P...
12/29/2023 18:24:29

In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revea...

hc-wainwright--co-reiterates-buy-on-verona-pharma-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Vero...
12/29/2023 13:28:27

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

why-rayzebio-shares-are-trading-higher-by-100-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why RayzeBio Shares Are Trading Higher By ...
12/26/2023 18:48:21

Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acqui...

earnings-scheduled-for-november-2-2023
Earnings Scheduled For November 2, 2023
11/02/2023 08:56:34

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on...

verona-pharma-q3-epads-016-beats-028-estimate-cash-position-of-2574m
Verona Pharma Q3 EPADS $(0.16) Beats $(0.2...
11/02/2023 07:21:22

Verona Pharma (NASDAQ:VRNA) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.28)...

verona-pharma-will-present-additional-analyses-of-positive-phase-3-enhance-studies-in-copd-at-chest-2023
Verona Pharma Will Present Additional Anal...
10/03/2023 07:04:46

hc-wainwright--co-reiterates-buy-on-verona-pharma-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Vero...
09/11/2023 10:23:18

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $32 price...

fda-accepts-to-review-verona-pharmas-new-drug-application-for-ensifentrine-for-maintenance-treatment-of-chronic-obstructive-pulmonary-disease-with-pdufa-target-action-date-of-june-26-2024
FDA Accepts To Review Verona Pharma's New ...
09/11/2023 06:35:02

verona-pharma-to-share-further-insights-from-phase-3-enhance-1-copd-study-at-ers-international-congress-2023
Verona Pharma To Share Further Insights Fr...
09/06/2023 06:55:45

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION